


REFERENCES

Flowsheet Classification	Antibiotics Required
No comorbidities or risk factors for MRSA/PA	Doxycycline 100mg po BID
Comorbidities (chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia)	<p>1. Levofloxacin 750mg monotherapy OR</p> <p>2. Combination therapy with: Amoxicillin/clavulanate 875/125mg po BID OR cefdinir 300mg po BID PLUS Azithromycin 500mg po x1, then 250mg daily OR doxycycline 100mg po BID</p>
CURB-65 = 2 or PSI 70-90	<p>1. 500mg of Azithromycin IVPB & 2g of Ceftriaxone IVPB, OR</p> <p>2. 500mg of Azithromycin IVPB & 2g of Ampicillin IVPB, OR</p> <p>3. Levofloxacin 750mg IVPB</p>
CURB-65 ≥ 3 or PSI ≥ 90	<p>1. 500mg of Azithromycin IVPB & 2g of Ceftriaxone IVPB* OR</p> <p>2. 500mg of Azithromycin IVPB & 2g of Ampicillin IVPB** OR</p> <p>3. Levofloxacin 750mg IVPB*</p> <p>* Add Flagyl 500mg IVPB if only if there is suspicion/confirmation of lung abscess or empyema, but not required for just aspiration risk. Can substitute beta lactam coverage with Zosyn 4.5g IVPB</p> <p>** Substitute Unasyn 3g IVPB if concern for lung abscess or empyema</p>
MRSA/Pseudomonas Coverage	<p>Vancomycin 25mg/kg IVPB OR Linezolid 600mg IVPB PLUS</p> <p>1. Zosyn 4.5g , OR</p> <p>2. Cefepime 2g IVPB, OR</p> <p>3. Levofloxacin 750mg IVPB PLUS</p> <p>1. Tobramycin 7mg/kg IVPB OR</p> <p>2. Tobramycin Nebulization if Intubated</p>
Double Pseudomonal Coverage	<p>1. Zosyn 4.5g IVPB, OR</p> <p>2. Cefepime 2g IVPB, OR</p> <p>3. Levofloxacin 750mg IVPB PLUS</p> <p>1. Tobramycin 7mg/kg IVPB, OR</p> <p>2. Tobramycin Nebulization if Intubated</p>

Pneumonia Protocol References

1. Alzahrani SA, Al-Salamah MA, Al-Madani WH, Elbarbary MA. Systematic review and meta-analysis for the use of ultrasound versus radiology in diagnosing of pneumonia. *Critical Ultrasound Journal*. 2017;9(1). doi:10.1186/s13089-017-0059-y.
2. Bi J, Yang J, Wang Y, et al. Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis. *Plos One*. 2016;11(11). doi:10.1371/journal.pone.0165942.
3. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *The Lancet*. 2015;385(9977):1511-1518. doi:10.1016/s0140-6736(14)62447-8.
4. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis. *Clinical Infectious Diseases*. 2013;58(3):330-339. doi:10.1093/cid/cit734.
5. Chavez MA, Shams N, Ellington LE, et al. Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis. *Respiratory Research*. 2014;15(1):50. doi:10.1186/1465-9921-15-50.
6. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone Infusion for Severe Community-acquired Pneumonia. *American Journal of Respiratory and Critical Care Medicine*. 2005;171(3):242-248. doi:10.1164/rccm.200406-808oc.
7. Corradi F, Brusasco C, Garlaschi A, et al. Quantitative Analysis of Lung Ultrasonography for the Detection of Community-Acquired Pneumonia: A Pilot Study. *BioMed Research International*. 2015;2015:1-8. doi:10.1155/2015/868707.
8. Efficacy And Safety Of Glucocorticoids In The Treatment Of Severe Community-Acquired Pneumonia: A Meta - Analysis. *Respirology*. 2018;23:120-120. doi:10.1111/resp.13420_82.
9. Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. *Critical Care*. 2011;15(2). doi:10.1186/cc10103.
10. Gross AE, Schooneveld TCV, Olsen KM, et al. Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia. *Antimicrobial Agents and Chemotherapy*. 2014;58(9):5262-5268. doi:10.1128/aac.02582-14.
11. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *American Journal of Respiratory and Critical Care Medicine*. 2005;171(4):388-416. doi:10.1164/rccm.200405-644st.
12. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*. 2016;63(5). doi:10.1093/cid/ciw353.

13. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes R. Epidemiology and Outcomes of Health-care–Associated Pneumonia. *Chest*. 2005;128(6):3854-3862.
doi:10.1378/chest.128.6.3854.
14. Liu X-L, Lian R, Tao Y-K, Gu C-D, Zhang G-Q. Lung ultrasonography: an effective way to diagnose community-acquired pneumonia. *Emergency Medicine Journal*. 2014;32(6):433-438.
doi:10.1136/emermed-2013-203039.
15. Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J. Accuracy of Lung Ultrasonography in the Diagnosis of Pneumonia in Adults. *Chest*. 2017;151(2):374-382.
doi:10.1016/j.chest.2016.10.039.
16. Long L, Zhao H-T, Zhang Z-Y, Wang G-Y, Zhao H-L. Lung ultrasound for the diagnosis of pneumonia in adults. *Medicine*. 2017;96(3). doi:10.1097/md.0000000000005713.
17. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 2011;377(9782):2023-2030. doi:10.1016/s0140-6736(11)60607-7.
18. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2013;62(3):439-445. doi:10.1016/j.ejcdt.2013.03.009.
19. Orso D, Guglielmo N, Copetti R. Lung ultrasound in diagnosing pneumonia in the emergency department. *European Journal of Emergency Medicine*. 2018;25(5):312-321.
doi:10.1097/nej.0000000000000517.
20. Sabry NA, Omar EE-D. Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. *Pharmacology & Pharmacy*. 2011;02(02):73-81.
doi:10.4236/pp.2011.22009.
21. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. *Cochrane Database of Systematic Reviews*. 2017.
doi:10.1002/14651858.cd007720.pub3.
22. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. *21 Acute Critical Care*. 2015.
doi:10.1183/13993003.congress-2015 oa3267.
23. Xia Y, Ying Y, Wang S, Li W, Shen H. Effectiveness of lung ultrasonography for diagnosis of pneumonia in adults: a systematic review and meta-analysis. *Journal of Thoracic Disease*. 2016;8(10):2822-2831. doi:10.21037/jtd.2016.09.38.
24. Ye X, Xiao H, Chen B, Zhang S. Accuracy of Lung Ultrasonography versus Chest Radiography for the Diagnosis of Adult Community-Acquired Pneumonia: Review of the Literature and Meta-Analysis. *Plos One*. 2015;10(6). doi:10.1371/journal.pone.0130066.
25. Schuetz, P., Christ-Crain, M., Thomann, R., Falconnier, C., Wolbers, M., Widmer, I., ... Group, for the P. S. (2009). Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The ProHOSP Randomized Controlled Trial. *JAMA*, 302(10), 1059–1066. <https://doi.org/10.1001/jama.2009.1297>

26. Schuetz, P et al. (2018, January). Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: A patient level meta-analysis. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29037960>
27. Murdoch et al. (2017). The Diagnostic Utility of Induced Sputum Microscopy and Culture in Childhood Pneumonia. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 64.
28. García-Vázquez et al. (2004). Assessment of the Usefulness of Sputum Culture for Diagnosis of Community-Acquired Pneumonia Using the PORT Predictive Scoring System. Archives of internal medicine. 164.
29. Waterer, Grant & Wunderink, Richard. (2001). The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respiratory medicine. 95. 78-82. 10.1053/rmed.2000.0977.
30. Campbell, Samuel & J Marrie, Thomas & Anstey, Rosemary & Dickinson, Garth & Ackroyd-Stolarz, Stacy. (2003). The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia - A prospective observational study. Chest. 123. 1142-50. 10.1378/chest.123.4.1142.
31. Lee, Jong Hoo & Hyung Kim, Yee. (2016). Predictive factors of true bacteremia and the clinical utility of blood cultures as a prognostic tool in patients with community-onset pneumonia. Medicine. 95.
32. S. Lee, Jonathan & L. Giesler, Daniel & F. Gellad, Walid & Fine, Michael. (2016). Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia. JAMA. 315. 593. 10.1001/jama.2016.0115.
33. Pakhale, Smita & Mulpuru, Sunita & Jm Verheij, Theo & M Kochen, Michael & Rohde, Gernot & Bjerre, Lise. (2014). Antibiotics for community-acquired pneumonia in adult outpatients. The Cochrane database of systematic reviews. 10. CD002109. 10.1002/14651858.CD002109.pub4.
34. Marti, Christophe & Garin, Nicolas & Grosgurin, Olivier & Poncet, Antoine & Combescure, Christophe & Carballo, Sebastian & Perrier, Arnaud. (2012). Prediction of severe community-acquired pneumonia: A systematic review and meta-analysis. Critical care (London, England). 16. R141. 10.1186/cc11447.
35. Ehsanpoor, Babak & Vahidi, Elnaz & Seyedhosseini, Javad & Jahanshir, Amirhosein. (2018). Validity of SMART-COP score in prognosis and severity of community acquired pneumonia in the emergency department. The American Journal of Emergency Medicine. 10.1016/j.ajem.2018.10.044.